Analyst Reco. Sartorius Stedim Biotech OTC Markets

Equities

Market Closed - OTC Markets Other stock markets 12:16:14 10/07/2024 am IST			5-day change	1st Jan Change
176.2 ^USD	+0.69%		0.00%	-33.19%

10/07	Markets Powered by Alternating Current
09/07	Mixed feelings

Oddo BHF Upgrades Sartorius Stedim Biotech to Outperform from Neutral, Lowers PT	04/07	MT
SARTORIUS STEDIM BIOTECH : Gets a Neutral rating from Barclays	27/06	ZD
SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%)	03/06
Sartorius sinks again towards year low	16/05	DP
SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	23/04	ZD
Sartorius Stedim: in the red with brokerage comments	22/04	CF
UBS Cuts Sartorius Stedim Biotech PT, Maintains at Neutral	22/04	MT
SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss	22/04
SARTORIUS STEDIM : UBS reduces target price	22/04	CF
SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating	12/03	ZD
SARTORIUS STEDIM BIOTECH : FY23: Updated mid-term outlook offers much-valued ‘certainty’	30/01
SARTORIUS STEDIM : UBS raises its target price	29/01	CF
Sartorius thwarted by 21-day line - despite HSBC recommendation	10/01	DP
JPMORGAN : Sartorius outlook likely to be share price driver	02/01	DP
SARTORIUS STEDIM BIOTECH : Opinion change, from Buy to Add	19/12
Sartorius continues to slide - low since April 2020	23/23/23	DP
Sartorius and subsidiary recover - JPMorgan praises biotech orders	19/23/19	DP
SARTORIUS STEDIM BIOTECH : Disappointing preliminary Q3 23 puts mid-term outlook in question	17/23/17
Profit warning weighs heavily on Sartorius and subsidiary Stedim	13/23/13	DP
SARTORIUS STEDIM BIOTECH : Jefferies reiterates its Buy rating	29/23/29	ZD

No results for this search

SARTORIUS STEDIM BIOTECH : EPS cut (2023: -13.7%, 2024: -16.4%)

June 03, 2024 at 01:02 pm IST